Brokerages predict that Organovo Holdings Inc (NASDAQ:ONVO) will report earnings of ($0.08) per share for the current quarter, according to Zacks. Two analysts have made estimates for Organovo’s earnings. Organovo posted earnings of ($0.07) per share during the same quarter last year, which would suggest a negative year over year growth rate of 14.3%. The firm is expected to announce its next earnings results on Thursday, February 14th.
According to Zacks, analysts expect that Organovo will report full-year earnings of ($0.28) per share for the current fiscal year, with EPS estimates ranging from ($0.28) to ($0.27). For the next fiscal year, analysts expect that the business will report earnings of ($0.30) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for Organovo.
Organovo (NASDAQ:ONVO) last issued its quarterly earnings data on Thursday, November 8th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.03. Organovo had a negative return on equity of 65.73% and a negative net margin of 732.47%. The business had revenue of $0.94 million for the quarter, compared to the consensus estimate of $0.90 million.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. LPL Financial LLC lifted its position in Organovo by 61.9% during the first quarter. LPL Financial LLC now owns 123,023 shares of the medical research company’s stock worth $127,000 after buying an additional 47,042 shares during the period. Vanguard Group Inc. increased its stake in Organovo by 1.1% during the third quarter. Vanguard Group Inc. now owns 4,771,558 shares of the medical research company’s stock worth $5,487,000 after acquiring an additional 52,073 shares during the last quarter. BlackRock Inc. increased its stake in Organovo by 1.5% during the third quarter. BlackRock Inc. now owns 7,068,897 shares of the medical research company’s stock worth $8,129,000 after acquiring an additional 102,486 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Organovo in the third quarter valued at about $138,000. Finally, UBS Group AG grew its stake in shares of Organovo by 44.4% in the first quarter. UBS Group AG now owns 888,385 shares of the medical research company’s stock valued at $915,000 after buying an additional 273,029 shares in the last quarter. Hedge funds and other institutional investors own 35.91% of the company’s stock.
Shares of NASDAQ:ONVO traded down $0.01 on Friday, hitting $1.02. The company had a trading volume of 139,215 shares, compared to its average volume of 486,601. Organovo has a 52-week low of $0.90 and a 52-week high of $2.09. The company has a market capitalization of $119.37 million, a P/E ratio of -3.19 and a beta of 2.51.
Organovo Company Profile
Organovo Holdings, Inc, a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Further Reading: Hedge Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.